In 2024 the life sciences sector experienced high levels of cost pressure that drove process transformation in regulatory functions and smarter use of data and human...

Amidst the “burgeoning” interest in developing novel optical imaging drugs and imaging devices to assist various standard surgical procedures, the US Food and Drug A...

As we advance through 2025, biopharma companies are increasingly using artificial intelligence (AI) and new data tools to improve commercial performance and make res...

We are at an important inflection point in our identification and understanding of genetically based diseases, particularly rarer paediatric-onset disorders that imp...

Insights from the Bio-Hermes Trial A New Perspective on Alzheimer's Research Alzheimer's disease (AD) presents a significant challenge, not only for those diagnos...

Q1: Why are highly potent active pharmaceutical ingredients (HPAPIs) playing a transformative role in oncology drug development? A: The rise of precision oncology...